Brendan Shaw

Brendan Shaw
Principal at Shawview Consulting For over 30 years Brendan has engaged in how the public and private sectors interact, collaborate and support each other. He has been in and around contentious policy and political debates through all that time. Brendan’s unique skill set is using credible argument, strategic thinking and a collaborative approach to build bridges and find new solutions to policy problems. An economist and political scientist by training, Brendan is an experienced CEO, advocate, board member and policy expert. ​ Brendan founded Shawview Consulting in 2017 based in London. Prior to his current role, he spent almost three …
Principal at Shawview Consulting

For over 30 years Brendan has engaged in how the public and private sectors interact, collaborate and support each other. He has been in and around contentious policy and political debates through all that time. Brendan’s unique skill set is using credible argument, strategic thinking and a collaborative approach to build bridges and find new solutions to policy problems. An economist and political scientist by training, Brendan is an experienced CEO, advocate, board member and policy expert.

Brendan founded Shawview Consulting in 2017 based in London. Prior to his current role, he spent almost three years as Assistant Director General of the International Federation of Pharmaceutical Manufacturers and Associations in Geneva, Switzerland working on global health issues with international organisations, pharmaceutical companies, national pharmaceutical industry associations and NGOs. Previously, Brendan worked over 11 years at Medicines Australia, the association for the Australian pharmaceutical industry, the first six years as its Executive Director, Health Policy and Research, before leading the organisation for five years as its Chief Executive. During this time Brendan has held several key positions on government and NGO bodies. He has also worked as an economist in government, consulting and academia, and as a policy adviser in the Australian parliament. Brendan holds an economics degree with honours in public administration from the University of Queensland and a PhD in management, business and economics from Monash University.

brendan@shawview.com
+44 (0) 7551 625 219
See more

Articles: Brendan Shaw

Changing Ourselves to Change the World: Engaging in India’s Pharma Development Strategy

India / Regular contributor Brendan Shaw gives his informed take on how best international stakeholders can engage with India’s attempts to transform into a global pharma innovation powerhouse,   Our greatest ability as humans is not to change the world, but to change ourselves Mahatma Gandhi The secret to success in India is to expect the unexpected.…

Time to Build More Windmills: Reflections from the ChinaBio Innovation and Investment Conference 2023

China / After four years away, Brendan Shaw recently returned to China to attend the ChinaBio Innovation and Investment Conference in Suzhou. Although geopolitical tensions, the fallout from COVID-19, and local market challenges have dampened stakeholder optimism around China somewhat in the last few years, Shaw feels that the country still has a lot to offer canny…

Universal Health Coverage at the Half-Way Point: Political Disappointment & Business Opportunity

Global / Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road still to travel if the goal of securing UHC for the world’s population by 2030 is to be met. Shaw outlines his recommendations for what…

The 2023 WHO Essential Medicines List & The Importance of Industry Engagement

Global / Regular contributor Brendan Shaw* casts his eye over the recently announced 2023 WHO Essential Medicines List, how it reflects growing pharmaceutical innovation, and why maintaining a ‘seat at the table’ for the pharma industry in these discussions will be crucial to meeting global healthcare access goals.   Recently, the World Health Organization (WHO) released its…

Back to the Future? Global Pandemic Treaty Negotiations Rumble On

Global / Brendan Shaw examines the protracted efforts of global stakeholders to come together around a global pandemic treaty and outlines the benefits of constructive engagement on the part of the pharmaceutical industry to find new solutions, policy approaches and business models moving forward.    You never want a serious crisis to go to waste Rahm Emanuel,…

The Magic, Myths & Fantasy of ESG: What Does it Mean for Pharma?

Global / Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises and capitalise on doing good while achieving commercial success.   It is our choices, Harry, that show what we truly are, far more than our…

Will We Try to Forget the Pandemic in 2023? Five Key Trends

Global / Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now in the rear-view mirror for much of the world, Shaw questions whether the lessons and progress that the pandemic brought will be built on in…

Arm Doors and Cross-Check: What the Health Sector Can Learn from the Post-COVID Airline Industry Debacle

Global / The news is filled with stories of woe in the airline industry. Bags being lost, flights being cancelled, planes being stranded on the tarmac, hours – days even – spent stranded at airports waiting for services promised but never delivered. Both the airline and health sectors have been hit by a multitude of post-COVID supply-side…

Pharmaceuticals Take Centre Stage in Australian Election Campaign

Australia / Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the first national election since the start of the COVID-19 pandemic, and it resulted in an historic change of government. The previous ruling conservative Liberal-National Coalition…

Pharma Industry Taking Lead to Safely Manufacture Antibiotics

Global / Antimicrobial pollution is a major global health and environmental risk. Shawview Consulting’s Brendan Shaw and Nicolai Schaaf of SIWI uncover what antibiotics manufacturers are doing about it.   Last month, global leaders issued an urgent call for all countries to reduce antimicrobial pollution. This includes the safe disposal of antimicrobial waste from manufacturing facilities. Antimicrobial…

Is 2022 the Pharma Industry’s ‘Call of Duty’ Moment?

Global / Taking the massive Microsoft acquisition of videogame company Activision Blizzard as his jumping-off point, Shawview Consulting’s Brendan Shaw lays out six key life science industry trends to watch in the coming year and wonders whether 2022 will be pharma’s ‘Call of Duty’ moment.   A few weeks ago, 2022 started with the news that Microsoft…

The Global Pandemic Agreement: Time to Get Serious

Global / Shawview Consulting’s Brendan Shaw laments the descent into nationalism that COVID-19 – like past pandemics – has led to, and outlines his hopes that the World Health Assembly’s new accord on pandemic prevention, preparedness and response will lead to a more unified, global approach to future pandemics.   When Professor Eddie Holmes of the University…

100 Years of Insulin: An Access to Medicines Issue Writ Large

Global / On the 100th anniversary of the development of insulin, regular PharmaBoardroom contributor Brendan Shaw* examines the shocking global disparities in access to the lifesaving drug, but does not point the finger of blame at the pharmaceutical industry. Instead, Shaw highlights the high barriers of entry that dissuade these companies from entering certain markets and calls…

The 2021 WHO Essential Medicines List: How Pharma Can Turn Challenge into Opportunity

Global / Shawview Consulting’s Brendan Shaw examines the WHO’s recently released updated Essential Medicines List. Shaw highlights some of the key trends and new inclusions in the List, why pricing and transparency are hotter topics than ever, and how pharma can incorporate this important document and its implications into their strategies for their own benefit, as well…

Opportunities for the Life Science Industry in Australia post-COVID

Australia / Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life sciences industry to invest in new facilities, research and development in a post-pandemic world.   Australia, the island continent A combination of early strict border…

Five Trends for Life Science Companies to Watch in 2021

Global / After a transformative 2020, Shawview Consulting’s Brendan Shaw looks into his crystal ball and makes five predictions (plus one) on the key trends that life sciences companies need to be aware of in 2021.   If 2020 taught us anything, it is that futurists and forecasters make their new year predictions at their peril. Every…

This Could Get Messy: Trump’s New ‘Most Favoured Nation’ Executive Order on Medicine Pricing

USA / Regular PharmaBoardroom contributor Brendan Shaw weighs in on the potential implications for US pharma of President Donald Trump’s latest executive order on medicine pricing, its wider impact on other high income economies, and why a Democratic victory in the upcoming presidential election will not see this issue go away.   The days of global freeriding…

When Health Policy Becomes Industrial Policy

Opinion / In his latest piece, Brendan Shaw casts his eye over why those drawing up health policies need to start incorporating issues of industrial policy into their long-term planning in order to secure investments into the right kinds of R&D and to help build a more open and collaborative innovation ecosystem.   “Scientists were close to…

Drones are Taking Off in Healthcare

Opinion / Brendan Shaw takes a look at the rise of drone technology in medical product delivery and its implications for the future of healthcare.   What was once thought of as science fiction even a few years ago is rapidly becoming a commercial reality. While we have not yet seen regular direct-to-patient deliveries of medicines by…

When Globalisation Knocks: Global Crises, COVID-19 and the Health Reform Agenda

Coronavirus / Shawview Consulting’s Brendan Shaw makes a compelling case for why the ongoing coronavirus pandemic should lead to a rethinking of how healthcare works across the globe.   Global crises can trigger major reform and Covid19 should trigger a reform of our health systems.   9/11 and the GFC When two jet airliners hit the twin…

Politics & Markets: The Role of the Private Sector in Universal Health Coverage

Opinion / Brendan Shaw outlines the long road still to travel to meet the UN Sustainable Development goal of ensuring basic healthcare financing for every citizen in the world by 2030 and the vital role that the private sector must play in attempting to meet this challenge.   The majority of developing countries will fail to achieve…

History Repeats with the Release of the 2019 WHO Essential Medicines List

Opinion / Brendan Shaw, Principal of Shawview Consulting and Adjunct Senior Lecturer at the University of New South Wales, shares highlights from the 2019 World Health Organization’s List of Essential Medicines.   The most recent edition of the World Health Organization’s Model List of Essential Medicines was released on 9 July and there are new additions and…

Shooting For the Stars: The Evolution in Outcome-Based Payment Models for Medicines

Opinion / Brendan Shaw* outlines the benefits that greater adoption of outcome-based payment models for medicines can bring, highlights recent successful implementations, and explains why policy updates are so important to ensuring a more comprehensive rollout of these models around the globe.   We’re looking forward to being one customer of many customers in a robust commercial…

The WHO’s Essential Medicines List: Changing the Conversation

WHO / Brendan Shaw outlines how a new approach to the WHO’s Essential Medicines List is needed to ensure both the patients of today and of the future can access the medicines they need.   For pharmaceutical companies, listing on the EML can be a double-edged sword. More than 40 years after its first release, the World Health…

We Need to Talk About Pharma Profits

Opinion / Brendan Shaw is principal at Shawview Consulting, a specialised consulting and advisory firm for public and private sector leaders in the areas of government-business relations, policy and strategic change, with a focus on the health and pharmaceutical sectors. He is also Adjunct Senior Lecturer in Pharmaceutical Medicine, School of Medical Sciences at the University of New…

See more